Plus Therapeutics, Inc.
Plus Therapeutics, Inc., headquartered in the United States, is a pioneering biotechnology company focused on developing innovative therapies for cancer treatment. Founded in 2016, the company has made significant strides in the field of radiopharmaceuticals, particularly with its lead product, Rhenium-186 NanoLiposome, designed for targeted cancer therapy.
With a commitment to advancing treatment options, Plus Therapeutics operates primarily in the oncology sector, leveraging its proprietary technology to enhance the delivery of therapeutic agents. The company has garnered attention for its unique approach to radiotherapy, positioning itself as a leader in the development of next-generation cancer treatments. Notable achievements include successful clinical trials that underscore its potential to improve patient outcomes in challenging cancer types.
-20 vs industry average
Plus Therapeutics, Inc.’s score of 18 is lower than 33% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Plus Therapeutics, Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Reported emissions
No reported emissions data is available for Plus Therapeutics, Inc. yet.
Plus Therapeutics, Inc.'s reported carbon emissions
Plus Therapeutics, Inc., headquartered in the US, currently does not report any carbon emissions data, as there are no available figures for kg CO2e emissions. Additionally, the company has not established any specific reduction targets or initiatives related to climate commitments. Without emissions data or defined climate strategies, it is challenging to assess their environmental impact or commitments within the industry context. As such, Plus Therapeutics appears to be in the early stages of developing a comprehensive approach to carbon management and sustainability.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Plus Therapeutics, Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Plus Therapeutics, Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisations
Plus Therapeutics, Inc.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project